BI 1467335 strongly inhibited AOC3 in participants with NASH, with doses ≥3 mg dose-dependently reducing the levels of liver injury biomarkers, ALT and CK-18. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.